Infant Bacterial Therapeutics AB (publ) Cash Flow Conversion Efficiency

Latest as of September 2025: -0.420x

Infant Bacterial Therapeutics AB (publ) cash flow conversion efficiency. Based on the latest financial reports, Infant Bacterial Therapeutics AB (publ) (IBT-B) has a cash flow conversion efficiency ratio of -0.420x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-52.25 Million ≈ $-5.62 Million USD) by net assets (Skr124.36 Million ≈ $13.38 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Infant Bacterial Therapeutics AB (publ) (2014–2024)

Cash flow conversion efficiency of Infant Bacterial Therapeutics AB (publ) from 2014 to 2024. This chart illustrates how Infant Bacterial Therapeutics AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View IBT-B stock price for real-time trading data and today's change.

Infant Bacterial Therapeutics AB (publ) Cash Flow Conversion Ratio Explained

Infant Bacterial Therapeutics AB (publ) cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Infant Bacterial Therapeutics AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Infant Bacterial Therapeutics AB (publ) ranked by their cash flow conversion efficiency. Also see Infant Bacterial Therapeutics AB (publ) stock valuation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Phoenix Tours International Inc TW:5706	-0.001x
OCK Group Bhd KLSE:0172	-0.030x
TCM Group CO:TCM	0.087x
Atlas Resources Tbk JK:ARII	0.071x
Idsud S.A PA:ALIDS	-0.907x
Multicampus Corporation KQ:067280	0.001x
Gandhi Special Tubes Limited NSE:GANDHITUBE	0.082x
Takarék Jelzálogbank Nyrt F:FH21	-0.130x

Annual Cash Flow Conversion Efficiency for Infant Bacterial Therapeutics AB (publ) (2014–2024)

The table below shows the annual cash flow conversion efficiency of Infant Bacterial Therapeutics AB (publ) from 2014 to 2024. Review IBT-B FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr170.26 Million ≈ $18.32 Million	Skr-113.13 Million ≈ $-12.17 Million	-0.664x	-100.32%
2023-12-31	Skr305.15 Million ≈ $32.84 Million	Skr-101.22 Million ≈ $-10.89 Million	-0.332x	-28.24%
2022-12-31	Skr331.71 Million ≈ $35.70 Million	Skr-85.80 Million ≈ $-9.23 Million	-0.259x	-83.79%
2021-12-31	Skr395.25 Million ≈ $42.54 Million	Skr-55.62 Million ≈ $-5.99 Million	-0.141x	-6.08%
2020-12-31	Skr440.15 Million ≈ $47.37 Million	Skr-58.39 Million ≈ $-6.28 Million	-0.133x	-31.98%
2019-12-31	Skr510.40 Million ≈ $54.93 Million	Skr-51.30 Million ≈ $-5.52 Million	-0.101x	-18.03%
2018-12-31	Skr556.72 Million ≈ $59.91 Million	Skr-47.41 Million ≈ $-5.10 Million	-0.085x	+58.75%
2017-12-31	Skr168.37 Million ≈ $18.12 Million	Skr-34.76 Million ≈ $-3.74 Million	-0.206x	+45.34%
2016-12-31	Skr105.23 Million ≈ $11.32 Million	Skr-39.75 Million ≈ $-4.28 Million	-0.378x	-65.99%
2015-12-31	Skr74.81 Million ≈ $8.05 Million	Skr-17.02 Million ≈ $-1.83 Million	-0.228x	+33.45%
2014-12-31	Skr11.03 Million ≈ $1.19 Million	Skr-3.77 Million ≈ $-405.93K	-0.342x	--

About Infant Bacterial Therapeutics AB (publ)

ST:IBT-B Sweden Biotechnology

Market Cap

$108.85 Million

Skr1.01 Billion SEK

Market Cap Rank

#18691 Global

#322 in Sweden

Share Price

Skr77.70

Change (1 day)

+3.60%

52-Week Range

Skr43.45 - Skr82.80

All Time High

Skr266.00